Dr. Reddy's Laboratories
146 hedge funds and large institutions have $770M invested in Dr. Reddy's Laboratories in 2018 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 55 increasing their positions, 33 reducing their positions, and 13 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
169% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 13
139% more call options, than puts
Call options by funds: $1.19M | Put options by funds: $497K
67% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 33
18% more capital invested
Capital invested by funds: $651M → $770M (+$120M)
17% more funds holding
Funds holding: 125 → 146 (+21)
4.57% more ownership
Funds ownership: 56.95% → 61.52% (+4.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CLC
Charles-Lim Capital
Central,
Hong Kong
|
+$14.5M |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$10.6M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$9.78M |
| 4 |
BlackRock
New York
|
+$8.54M |
| 5 |
Renaissance Technologies
New York
|
+$8.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Trust Advisors
Wheaton,
Illinois
|
-$7.52M |
| 2 |
Millennium Management
New York
|
-$6.44M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$4.88M |
| 4 |
NMC
Nine Masts Capital
Central,
Hong Kong
|
-$3.31M |
| 5 |
CBOA
Commonwealth Bank of Australia
Sydney, NSW,
Australia
|
-$2.63M |
RDY Hedge Fund Activity: Q4 2018 in Review
146 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Dr. Reddy's Laboratories (RDY) for Q4 2018, worth a combined $770M — up 18% from $651M a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new RDY positions and 13 closed out — a net gain of 22 holders — while 55 added to existing stakes and 33 trimmed.
The largest buyer was Charles-Lim Capital, opening a new position worth an estimated $14.5M. The largest seller was First Trust Advisors, cutting an estimated $7.52M.
- 146 institutional investors held Dr. Reddy's Laboratories (RDY) as of Q4 2018, up from 125 in Q3 2018.
- Funds reported $770M of Dr. Reddy's Laboratories stock for Q4 2018, up 18% quarter-over-quarter.
- 35 funds opened new Dr. Reddy's Laboratories positions in Q4 2018 and 13 closed out, a net change of +22 holders.
- The largest Dr. Reddy's Laboratories buyer in Q4 2018 was Charles-Lim Capital, an estimated $14.5M added.
- The largest Dr. Reddy's Laboratories seller in Q4 2018 was First Trust Advisors, an estimated $7.52M sold.
Based on aggregated 13F filings for Q4 2018.